- Therapeutic Cataract & Refractive
- Lens Technology
- Glasses
- Ptosis
- Comprehensive Eye Exams
- AMD
- COVID-19
- DME
- Ocular Surface Disease
- Optic Relief
- Geographic Atrophy
- Cornea
- Conjunctivitis
- LASIK
- Myopia
- Presbyopia
- Allergy
- Nutrition
- Pediatrics
- Retina
- Cataract
- Contact Lenses
- Lid and Lash
- Dry Eye
- Glaucoma
- Refractive Surgery
- Comanagement
- Blepharitis
- OCT
- Patient Care
- Diabetic Eye Disease
- Technology
Kala Pharmaceuticals: EYSUVIS now covered on UnitedHealthcare Commercial, Cigna Medicare
Effective this month, the coverage applies to approximately 70% of all United Healthcare commercial lives.
United Healthcare has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on the company’s commercial formularies, Kala Pharmaceuticals announced on Tuesday.
Effective this month, the coverage applies to approximately 70% of all commercial lives — 118 million individuals, according to a news release.
Further, Cigna Medicare has also added EYSUVIS as a preferred brand, effective February 2022, Kala stated. With this latest addition, EYSUVIS has coverage via Medicare for select plans with Express Scripts, Prime Therapeutics, and Cigna — totaling 15% of all Medicare lives.
EYSUVIS became commercially available in January 2021. It is the first and only FDA-approved medicine for short-term treatment of the signs and symptoms of dry eye.
